- Lexaria Bioscience is dedicated to applying its patented technology to pharmaceutical drug offerings to enhance their performance and speed their rate of effective use
- The company’s flagship DehydraTECH(TM) technology has delivered numerous successes in studies of its potential for treating high blood pressure and heart disease, nicotine addiction, and virus infection
- Most recently, the company reported successes in increasing the speed and effectiveness in a drug treating erectile dysfunction (“ED”) in laboratory animals
- Lexaria is preparing an investigational new drug (“IND”) application for its hypertension line of study with the aim of achieving a new drug application (“NDA”) approval from the FDA
The recent announcement that drug bio-effectiveness innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology may be useful in erectile dysfunction therapy by enhancing the speed of effectiveness of medication sildenafil (common as Viagra) follows on a number of developmental successes reported by Lexaria.
DehydraTECH is a proprietary technology that changes how the body detects and absorbs drugs by combining active pharmaceutical ingredients (“APIs”) with a fatty acid oil, applying it to a food or other type of carrier particle, synthesizing it through a dehydration procedure and rendering the resulting powder or liquid as a final product capable of being rapidly absorbed by the body without suffering reduced effectiveness through filtration by the body’s liver and digestive system.
Lexaria’s testing has focused on four basic areas of application — improving the treatment of heart disease and high blood pressure, delivering nicotine in a non-smoke form, improving the effectiveness of antiviral drugs and making CBD from hemp rapidly available without inhalation.
During the company’s 2021-2022 study program (https://cnw.fm/RdMLm) a number of successes have been reported. In the HYPER-A21-1 and 2 studies the company demonstrated enhancement in the amount of CBD delivered to lab animals’ bloodstreams and brain tissue, the HYPER-H21-1 and 2 studies showed improved blood pressure reduction and reduction of blood vessel stiffness in humans, and NIC-A21-1 revealed oral nicotine delivery peak levels that were 10 to 20 times faster and 10 times higher than those of the control substances.
The series VIRAL-C21-3, VIRAL-A20-2, VIRAL-MC21-1, and VIRAL-A20-3 showed inhibition of the COVID-19/SARS-CoV-2 virus, increased drug availability, and potential FDA-compliant prevention of new molecular entity (“NME”) creation utilizing antiviral drugs Remdesivir, Ebastine and Colchicine.
“Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products,” the company’s website states (https://cnw.fm/tWFOG). “Lexaria licenses its advanced technology to other companies around the world to offer consumers the best performance possible across an array of product formats.”
Currently, all of the company’s operations are fully funded through the second quarter of 2023. Revenues grew more than 150 percent between 2020 and 2021 as Lexaria uplisted to the Nasdaq Capital Markets.
The DehydraTECH-CBD human studies for treating hypertension are the most advanced as the company is in preparations for an investigational new drug (“IND”) application with the aim of filing for a new drug application (“NDA”) with the FDA.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
Receive Text Alerts from CBDWire: Text “Cannabis” to 21000
For more information please visit https://www.cbdwire.com and or https://CBDWire.News
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
